Objective
Chronic Kidney Disease (CKD) is one of the major causes of death in high income countries and its prevalence is growing rapidly. New therapies for the treatment of CKD have shown clear efficacy at a population level. Yet, individual patients respond differently with many patients showing suboptimal efficacy. This indicates that a ‘one size fits all’ approach is no longer sustainable.
Currently there are no validated pharmacodynamic biomarkers in CKD that aid in guiding optimal therapy for individual patients. Furthermore, there remains a large gap between biomarker research and actual implementation of biomarker based care in daily clinical practice.
Thus, there is an urgent need to validate and translate biomarkers as tools for daily clinical practice. PRIME-CKD has a unique advantage to address this challenge as it builds on recently discovered pharmacodynamic biomarkers for CKD treatment, and has access to a vast amount of clinical data, bio-samples. PRIME CKD will:
1) Provide a breakthrough in the pharmacotherapy of CKD with the validation and implementation of pharmacodynamic biomarkers which will advance personalized medicine.
2) Scientifically validate innovative clinical trial elements, pipelines and qualification procedures that can be used by researchers, diagnostics industries and regulatory authorities.
3) Establish a Stakeholder Network to truly engage patients, clinicians and other stakeholders in implementation of personalized medicines
4) Develop a roadmap for biomarker use in daily clinical practice for the optimal treatment of CKD.
These results will enable clinicians to match patients with CKD with the most effective available drug within the shortest possible timeframe leading to less disease burden and progression of disease, enhanced quality of life and increased cost-efficiency. PRIME-CKD results will thus unlock the potential of biomarkers in healthcare and close the gap between biomarker research and clinical use in daily practice.
Fields of science
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
9713 GZ Groningen
Netherlands
See on map
Participants (14)
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
9713 GZ Groningen
See on map
46109 1274 Ann Arbor
See on map
22100 Lund
See on map
3400 Hillerod
See on map
R95 NXR0 Kilkenny
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
20251 Hamburg
See on map
81100 Caserta
See on map
40126 Bologna
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
40138 Bologna
See on map
46010 Valencia
See on map
7364 AG Lieren
See on map
3531AH Utrecht
See on map
91054 Erlangen
See on map
1405 EE Bussum
See on map
Partners (2)
LE1 7RH Leicester
See on map
LE1 5WW Leicester
See on map